InsiderTrades.com logo
Thomas J. DesRosier net worth and biography
  • Phone
  • Email
  • Website

Thomas DesRosier Biography and Net Worth

EVP of Seres Therapeutics

Thomas J. DesRosier is the Executive Vice President, Chief Legal Officer and Secretary of Seres. He brings more than 30 years of experience in the biopharmaceutical industry. Prior to joining Seres, he served as Chief Legal and Administrative Officer at ARIAD Pharmaceuticals, and prior to that held the same position at Cubist Pharmaceuticals, where he led the negotiation of the acquisition of Cubist by Merck. Previous to that, he served as Senior Vice President and General Counsel, North America of Sanofi, a position he assumed in 2011 after Sanofi acquired Genzyme Corporation, where he was Senior Vice President and Chief Legal Officer. Prior to his 12-year tenure at Genzyme, Mr. DesRosier held senior legal positions at Wyeth Pharmaceuticals, predecessor Genetic Institute, and E.I. DuPont de Nemours. Mr. DesRosier serves on the board of directors of Avanir Pharmaceuticals where he is Chairman of both the Audit Committee and Compliance Committee. He received his B.A. in chemistry from the University of Vermont and his J.D. from Wake Forest University School of Law.

What is Thomas J. DesRosier's net worth?

The estimated net worth of Thomas J. DesRosier is at least $51,420.84 as of February 18th, 2025. Mr. DesRosier owns 7,122 shares of Seres Therapeutics stock worth more than $51,421 as of June 1st. This net worth evaluation does not reflect any other assets that Mr. DesRosier may own. Additionally, Mr. DesRosier receives an annual salary of $719,550.00 as EVP at Seres Therapeutics. Learn More about Thomas J. DesRosier's net worth.

How old is Thomas J. DesRosier?

Mr. DesRosier is currently 69 years old. There are 6 older executives and no younger executives at Seres Therapeutics. Learn More on Thomas J. DesRosier's age.

What is Thomas J. DesRosier's salary?

As the EVP of Seres Therapeutics, Inc., Mr. DesRosier earns $719,550.00 per year. There are 2 executives that earn more than Mr. DesRosier. The highest earning executive at Seres Therapeutics is Mr. Eric D. Shaff M.B.A., President, CEO & Director, who commands a salary of $1,020,000.00 per year. Learn More on Thomas J. DesRosier's salary.

How do I contact Thomas J. DesRosier?

The corporate mailing address for Mr. DesRosier and other Seres Therapeutics executives is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. Seres Therapeutics can also be reached via phone at (617) 945-9626 and via email at ctanzi@serestherapeutics.com. Learn More on Thomas J. DesRosier's contact information.

Has Thomas J. DesRosier been buying or selling shares of Seres Therapeutics?

Thomas J. DesRosier has not been actively trading shares of Seres Therapeutics during the past quarter. Most recently, Thomas Desrosier sold 215 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $16.20, for a transaction totalling $3,483.00. Following the completion of the sale, the executive vice president now directly owns 7,122 shares of the company's stock, valued at $115,376.40. Learn More on Thomas J. DesRosier's trading history.

Who are Seres Therapeutics' active insiders?

Seres Therapeutics' insider roster includes Thomas DesRosier (EVP), Matthew Henn (Insider), Eric Shaff (https://ir.pragroup.com/board-of-directors?item=14), and Teresa Young (Executive Vice President, Chief Commercial and Strategy Officer). Learn More on Seres Therapeutics' active insiders.

Are insiders buying or selling shares of Seres Therapeutics?

During the last twelve months, insiders at the biotechnology company sold shares 13 times. They sold a total of 3,569 shares worth more than $61,314.60. The most recent insider tranaction occured on February, 18th when insider Matthew R Henn sold 197 shares worth more than $3,191.40. Insiders at Seres Therapeutics own 4.7% of the company. Learn More about insider trades at Seres Therapeutics.

Information on this page was last updated on 2/18/2025.

Thomas J. DesRosier Insider Trading History at Seres Therapeutics

See Full Table

Thomas J. DesRosier Buying and Selling Activity at Seres Therapeutics

This chart shows Thomas Desrosier's buying and selling at Seres Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4k-$2k$0$2k$4kTotal Insider BuyingTotal Insider Selling

Seres Therapeutics Company Overview

Seres Therapeutics logo
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $7.22
Low: $6.84
High: $7.33

50 Day Range

MA: $9.57
Low: $6.77
High: $15.10

2 Week Range

Now: $7.22
Low: $6.53
High: $30.60

Volume

88,626 shs

Average Volume

146,299 shs

Market Capitalization

$63.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.89